☰

Mirkka Sarparanta - Publications

Affiliations: 
Memorial Sloan Kettering Cancer Center, Rockville Centre, NY, United States 
Tree Info Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Otaru S, Martinmäki T, Kuurne I, Paulus A, Helariutta K, Sarparanta M, Airaksinen AJ. Radiolabelling of peptides with tetrazine ligation based on the inverse electron-demand Diels-Alder reaction: rapid, catalyst-free and mild conversion of 1,4-dihydropyridazines to pyridazines. Rsc Advances. 13: 22606-22615. PMID 37501774 DOI: 10.1039/d3ra02807k  0.601
2022 Lambidis E, Chen CC, Lumén D, Sánchez AIF, Sarparanta M, Cheng RH, Airaksinen AJ. Biological evaluation of integrin αβ-targeted Ga-labeled HEVNPs in HCT 116 colorectal tumor-bearing mice. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 106336. PMID 36403717 DOI: 10.1016/j.ejps.2022.106336  0.595
2022 Lambidis E, Chen CC, Baikoghli M, Imlimthan S, Khng YC, Sarparanta M, Cheng RH, Airaksinen AJ. Development of Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET. Molecular Pharmaceutics. PMID 35857429 DOI: 10.1021/acs.molpharmaceut.2c00359  0.606
2022 Otaru S, Paulus A, Imlimthan S, Kuurne I, Virtanen H, Liljenbäck H, Tolvanen T, Auchynnikava T, Roivainen A, Helariutta K, Sarparanta M, Airaksinen AJ. Development of [F]AmBF Tetrazine for Radiolabeling of Peptides: Preclinical Evaluation and PET Imaging of [F]AmBF-PEG-Tyr-Octreotide in an AR42J Pancreatic Carcinoma Model. Bioconjugate Chemistry. PMID 35709482 DOI: 10.1021/acs.bioconjchem.2c00231  0.652
2022 Lambidis E, Lumén D, Koskipahta E, Imlimthan S, Lopez BB, Sánchez AIF, Sarparanta M, Cheng RH, Airaksinen AJ. Synthesis and ex vivo biodistribution of two Ga-labeled tetrazine tracers: Comparison of pharmacokinetics. Nuclear Medicine and Biology. PMID 35680503 DOI: 10.1016/j.nucmedbio.2022.05.004  0.609
2022 Lumen D, Vugts D, Chomet M, Imlimthan S, Sarparanta M, Vos R, Schreurs M, Verlaan M, Lang PA, Hippeläinen E, Beaino W, Windhorst AD, Airaksinen AJ. Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [Zr]Zr-DFO-PEG-Tz. Bioconjugate Chemistry. PMID 35442642 DOI: 10.1021/acs.bioconjchem.2c00164  0.643
2021 Keinänen O, Dayts EJ, Rodriguez C, Sarrett SM, Brennan JM, Sarparanta M, Zeglis BM. Harnessing PET to track micro- and nanoplastics in vivo. Scientific Reports. 11: 11463. PMID 34075133 DOI: 10.1038/s41598-021-90929-6  0.76
2021 Imlimthan S, Khng YC, Keinänen O, Zhang W, Airaksinen AJ, Kostiainen MA, Zeglis BM, Santos HA, Sarparanta M. A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma. Small (Weinheim An Der Bergstrasse, Germany). e2007705. PMID 33738957 DOI: 10.1002/smll.202007705  0.752
2021 Das S, Imlimthan S, Airaksinen AJ, Sarparanta M. Radiolabeling of Theranostic Nanosystems. Advances in Experimental Medicine and Biology. 1295: 49-76. PMID 33543455 DOI: 10.1007/978-3-030-58174-9_3  0.648
2021 Matović J, Järvinen J, Sokka IK, Imlimthan S, Raitanen JE, Montaser A, Maaheimo H, Huttunen KM, Peräniemi S, Airaksinen AJ, Sarparanta M, Johansson MP, Rautio J, Ekholm FS. Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and Evaluation of the Entire Positional Isomer Library of -Carboranylmethyl-Bearing Glucoconjugates. Molecular Pharmaceutics. 18: 285-304. PMID 33390018 DOI: 10.1021/acs.molpharmaceut.0c00917  0.609
2020 Lumen D, Wang S, Mäkilä E, Imlimthan S, Sarparanta M, Correia A, Westerveld Haug C, Hirvonen J, Santos HA, Airaksinen AJ, Filtvedt W, Salonen J. Investigation of silicon nanoparticles produced by centrifuge chemical vapor deposition for applications in therapy and diagnostics. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. PMID 33279602 DOI: 10.1016/j.ejpb.2020.11.022  0.598
2020 Matović J, Järvinen J, Bland HC, Sokka IK, Imlimthan S, Mateu Ferrando R, Huttunen KM, Timonen J, Peräniemi S, Aitio O, Airaksinen AJ, Sarparanta M, Johansson MP, Rautio J, Ekholm FS. Addressing the Biochemical Foundations of a Glucose-based "Trojan horse"-strategy to Boron Neutron Capture Therapy: From Chemical Synthesis to In Vitro Assessment. Molecular Pharmaceutics. PMID 32787269 DOI: 10.1021/Acs.Molpharmaceut.0C00630  0.635
2020 Otaru S, Niemikoski H, Sarparanta M, Airaksinen AJ. Metabolism of a Bioorthogonal PET Tracer Candidate [19F/18F]SiFA-Tetrazine in Mouse Liver Microsomes: Biotransformation Pathways and Defluorination Investigated by UHPLC-HRMS. Molecular Pharmaceutics. PMID 32539414 DOI: 10.1021/Acs.Molpharmaceut.0C00523  0.674
2020 Jakobsson U, Mäkilä E, Rahikkala A, Imlimthan S, Lampuoti J, Ranjan S, Heino J, Jalkanen P, Köster U, Mizohata K, Santos HA, Salonen J, Airaksinen AJ, Sarparanta M, Helariutta K. Preparation and in vivo evaluation of red blood cell membrane coated porous silicon nanoparticles implanted with Tb. Nuclear Medicine and Biology. 84: 102-110. PMID 32334356 DOI: 10.1016/J.Nucmedbio.2020.04.001  0.631
2020 Otaru S, Imlimthan S, Sarparanta M, Helariutta K, Wähälä K, Airaksinen AJ. Evaluation of Organo [F]Fluorosilicon Tetrazine as a Prosthetic Group for the Synthesis of PET Radiotracers. Molecules (Basel, Switzerland). 25. PMID 32156020 DOI: 10.3390/Molecules25051208  0.683
2020 Balasubramanian V, Domanskyi A, Renko JM, Sarparanta M, Wang CF, Correia A, Mäkilä E, Alanen OS, Salonen J, Airaksinen AJ, Tuominen R, Hirvonen J, Airavaara M, Santos HA. Engineered antibody-functionalized porous silicon nanoparticles for therapeutic targeting of pro-survival pathway in endogenous neuroblasts after stroke. Biomaterials. 227: 119556. PMID 31670035 DOI: 10.1016/J.Biomaterials.2019.119556  0.635
2019 Lumen D, Näkki S, Imlimthan S, Lambidis E, Sarparanta M, Xu W, Lehto VP, Airaksinen AJ. Site-Specific In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model. Pharmaceutics. 11. PMID 31861119 DOI: 10.3390/Pharmaceutics11120686  0.655
2019 Imlimthan S, Correia A, Figueiredo P, Lintinen K, Balasubramanian V, Airaksinen AJ, Kostiainen MA, Santos HA, Sarparanta M. Systematic In Vitro Biocompatibility Studies of Multimodal Cellulose Nanocrystal and Lignin Nanoparticles. Journal of Biomedical Materials Research. Part A. PMID 31794149 DOI: 10.1002/Jbm.A.36856  0.627
2019 Sarparanta M, Pourat J, Carnazza KE, Tang J, Paknejad N, Reiner T, Kostiainen MA, Lewis JS. Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer. Nuclear Medicine and Biology. 80: 1-12. PMID 31759312 DOI: 10.1016/J.Nucmedbio.2019.11.002  0.653
2018 Imlimthan S, Otaru S, Keinänen O, Correia A, Lintinen KS, Santos HA, Airaksinen AJ, Kostiainen MA, Sarparanta M. Radiolabeled Molecular Imaging Probes for the in Vivo Evaluation of Cellulose Nanocrystals for Biomedical Applications. Biomacromolecules. PMID 30380842 DOI: 10.1021/Acs.Biomac.8B01313  0.784
2018 Keinänen O, Partelová D, Alanen O, Antopolsky M, Sarparanta M, Airaksinen AJ. Efficient cartridge purification for producing high molar activity F-glycoconjugates via oxime formation. Nuclear Medicine and Biology. 67: 27-35. PMID 30380464 DOI: 10.1016/J.Nucmedbio.2018.10.001  0.773
2018 Karaman DŞ, Sarparanta MP, Rosenholm JM, Airaksinen AJ. Multimodality Imaging of Silica and Silicon Materials In Vivo. Advanced Materials (Deerfield Beach, Fla.). PMID 29388264 DOI: 10.1002/adma.201703651  0.622
2017 Keinänen O, Fung K, Pourat J, Jallinoja V, Vivier D, Pillarsetty NK, Airaksinen AJ, Lewis JS, Zeglis BM, Sarparanta M. Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. Ejnmmi Research. 7: 95. PMID 29198065 DOI: 10.1186/S13550-017-0344-6  0.733
2017 Keinänen O, Mäkilä EM, Lindgren R, Virtanen H, Liljenbäck H, Oikonen V, Sarparanta M, Molthoff C, Windhorst AD, Roivainen A, Salonen JJ, Airaksinen AJ. Pretargeted PET Imaging of trans-Cyclooctene-Modified Porous Silicon Nanoparticles. Acs Omega. 2: 62-69. PMID 28649670 DOI: 10.1021/acsomega.6b00269  0.793
2016 Demoin DW, Wyatt LC, Edwards KJ, Abdel-Atti D, Sarparanta MP, Pourat J, Longo VA, Carlin SD, Engelman DM, Andreev OA, Reshetnyak YK, Viola-Villegas N, Lewis JS. PET Imaging of Extracellular pH in Tumors with (64)Cu- and (18)F-labeled pHLIP peptides: A Structure-Activity Optimization Study. Bioconjugate Chemistry. PMID 27396694 DOI: 10.1021/Acs.Bioconjchem.6B00306  0.773
2016 Keinänen O, Li XG, Chenna NK, Lumen D, Ott J, Molthoff CF, Sarparanta M, Helariutta K, Vuorinen T, Windhorst AD, Airaksinen AJ. A New Highly Reactive and Low Lipophilicity Fluorine-18 Labeled Tetrazine Derivative for Pretargeted PET Imaging. Acs Medicinal Chemistry Letters. 7: 62-6. PMID 26819667 DOI: 10.1021/Acsmedchemlett.5B00330  0.787
2016 Demoin DW, Edwards KJ, Wyatt LC, Sarparanta M, Pourat J, Andreev OA, Reshetnyak YK, Viola-Villegas N, Lewis JS. Abstract 4205: Targeting a variety of cancers with NOTA-derivatized pH (low) insertion peptide (pHLIP) complexes with64Cu and18F: What cancers are targetable Cancer Research. 76: 4205-4205. DOI: 10.1158/1538-7445.Am2016-4205  0.548
2015 Wang CF, Sarparanta MP, Mäkilä EM, Hyvönen ML, Laakkonen PM, Salonen JJ, Hirvonen JT, Airaksinen AJ, Santos HA. Multifunctional porous silicon nanoparticles for cancer theranostics. Biomaterials. 48: 108-18. PMID 25701036 DOI: 10.1016/j.biomaterials.2015.01.008  0.644
2015 Yrjölä S, Sarparanta M, Airaksinen AJ, Hytti M, Kauppinen A, Pasonen-Seppänen S, Adinolfi B, Nieri P, Manera C, Keinänen O, Poso A, Nevalainen TJ, Parkkari T. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 67: 85-96. PMID 25447744 DOI: 10.1016/J.Ejps.2014.11.003  0.751
2014 Kallinen AM, Sarparanta MP, Liu D, Mäkilä EM, Salonen JJ, Hirvonen JT, Santos HA, Airaksinen AJ. In vivo evaluation of porous silicon and porous silicon solid lipid nanocomposites for passive targeting and imaging Molecular Pharmaceutics. 11: 2876-2886. PMID 24977922 DOI: 10.1021/mp500225b  0.68
2014 Kallinen A, Todorov B, Kallionpää R, Bäck S, Sarparanta M, Raki M, García-Horsman JA, Bergström KA, Wallén EA, Männistö PT, Airaksinen AJ. Synthesis and biological evaluation of novel (123)I-labeled 4-(4-iodophenyl)butanoyl-L-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo. European Journal of Medicinal Chemistry. 79: 436-45. PMID 24763264 DOI: 10.1016/J.Ejmech.2014.04.014  0.667
2014 Wang CF, Mäkilä EM, Kaasalainen MH, Liu D, Sarparanta MP, Airaksinen AJ, Salonen JJ, Hirvonen JT, Santos HA. Copper-free azide-alkyne cycloaddition of targeting peptides toporous silicon nanoparticles for intracellular drug uptake Biomaterials. 35: 1257-1266. PMID 24211082 DOI: 10.1016/j.biomaterials.2013.10.065  0.632
2012 Bimbo LM, Sarparanta M, Mäkilä E, Laaksonen T, Laaksonen P, Salonen J, Linder MB, Hirvonen J, Airaksinen AJ, Santos HA. Cellular interactions of surface modified nanoporous silicon particles. Nanoscale. 4: 3184-92. PMID 22508528 DOI: 10.1039/C2Nr30397C  0.619
2012 Rajecki M, Sarparanta M, Hakkarainen T, Tenhunen M, Diaconu I, Kuhmonen V, Kairemo K, Kanerva A, Airaksinen AJ, Hemminki A. SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I. Plos One. 7: e32871. PMID 22412937 DOI: 10.1371/Journal.Pone.0032871  0.618
2012 Sarparanta MP, Bimbo LM, Mäkilä EM, Salonen JJ, Laaksonen PH, Helariutta AM, Linder MB, Hirvonen JT, Laaksonen TJ, Santos HA, Airaksinen AJ. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials. 33: 3353-62. PMID 22285465 DOI: 10.1016/j.biomaterials.2012.01.029  0.599
2012 Sarparanta M, Bimbo LM, Rytkönen J, Mäkilä E, Laaksonen TJ, Laaksonen P, Nyman M, Salonen J, Linder MB, Hirvonen J, Santos HA, Airaksinen AJ. Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. Molecular Pharmaceutics. 9: 654-63. PMID 22277076 DOI: 10.1021/Mp200611D  0.67
2011 Sarparanta M, Mäkilä E, Heikkilä T, Salonen J, Kukk E, Lehto VP, Santos HA, Hirvonen J, Airaksinen AJ. ¹⁸F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography. Molecular Pharmaceutics. 8: 1799-806. PMID 21875120 DOI: 10.1021/Mp2001654  0.686
2011 Sarparanta M, Bimbo LM, Mäkilä E, Salonen J, Laaksonen T, Hirvonen J, Lehto V, Laaksonen P, Linder MB, Airaksinen AJ, Santos HA. Fluorine-18 radiolabeling as a tool to evaluate novel porous silicon based nano- and microcarriers for drug delivery Journal of Labelled Compounds and Radiopharmaceuticals. 54. DOI: 10.1002/Jlcr.1926  0.627
2010 Bimbo LM, Sarparanta M, Santos HA, Airaksinen AJ, Mäkilä E, Laaksonen T, Peltonen L, Lehto VP, Hirvonen J, Salonen J. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. Acs Nano. 4: 3023-32. PMID 20509673 DOI: 10.1021/Nn901657W  0.663
2009 Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA, Kairemo K, Hemminki A. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5396-403. PMID 19706820 DOI: 10.1158/1078-0432.Ccr-08-2571  0.61
Show low-probability matches.